{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:13:09Z","timestamp":1743221589272,"version":"3.40.3"},"publisher-location":"Cham","reference-count":17,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031734991"},{"type":"electronic","value":"9783031735004"}],"license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-73500-4_2","type":"book-chapter","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T03:58:55Z","timestamp":1731643135000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiling Atopic Dermatitis Patients Using Decision Tree Classifiers to Anticipate Dupilumab Response"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-9888","authenticated-orcid":false,"given":"Ana","family":"Duarte","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2157-8891","authenticated-orcid":false,"given":"Orlando","family":"Belo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold, L., et al.: Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials. Am. J. Clin. Dermatol.Clin. Dermatol. 24, 595\u2013607 (2023)","journal-title":"Am. J. Clin. Dermatol.Clin. Dermatol."},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000370226","volume":"66","author":"C Lifschitz","year":"2015","unstructured":"Lifschitz, C.: The impact of atopic dermatitis on quality of life. Ann. Nutr. Metab.Nutr. Metab. 66, 34\u201340 (2015)","journal-title":"Ann. Nutr. Metab.Nutr. Metab."},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/jdv.15609","volume":"33","author":"C Olesen","year":"2019","unstructured":"Olesen, C., Holm, J., N\u00f8rreslet, L., Serup, J., Thomsen, S., Agner, T.: Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J. Eur. Acad. Dermatol. Venereol.Dermatol. Venereol. 33, 1562\u20131568 (2019)","journal-title":"J. Eur. Acad. Dermatol. Venereol.Dermatol. Venereol."},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00441-023-03816-z","volume":"394","author":"S Ng","year":"2023","unstructured":"Ng, S., Masarone, S., Watson, D., Barnes, M.R.: The benefits and pitfalls of machine learning for biomarker discovery. Cell Tissue Res. 394, 17\u201331 (2023)","journal-title":"Cell Tissue Res."},{"key":"2_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaad.2019.12.034","volume":"82","author":"H Khosravi","year":"2020","unstructured":"Khosravi, H., Zhang, S., Anderson, A.M., Ferris, L.K., Choudhary, S., Patton, T.: Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J. Am. Acad. Dermatol.Dermatol. 82, 1023\u20131024 (2020)","journal-title":"J. Am. Acad. Dermatol.Dermatol."},{"key":"2_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"L Beck","year":"2014","unstructured":"Beck, L., et al.: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371, 130\u2013139 (2014)","journal-title":"N. Engl. J. Med."},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt, A., et al.: Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol.Dermatol. 157, 1047\u20131055 (2021)","journal-title":"JAMA Dermatol.Dermatol."},{"key":"2_CR8","doi-asserted-by":"crossref","unstructured":"Wu, J.J., et al.: Predictors of nonresponse to dupilumab in patients with atopic dermatitis: a machine learning analysis. Ann. Allergy, Asthma Immunol. 129, 354\u2013359 (2022)","DOI":"10.1016\/j.anai.2022.05.025"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"8193","DOI":"10.2147\/IJGM.S331119","volume":"14","author":"Y Zhong","year":"2021","unstructured":"Zhong, Y., Qin, K., Li, L., Liu, H., Xie, Z., Zeng, K.: Identification of immunological biomarkers of atopic dermatitis by integrated analysis to determine molecular targets for diagnosis and therapy. Int. J. Gen. Med. 14, 8193\u20138209 (2021)","journal-title":"Int. J. Gen. Med."},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaci.2022.02.001","volume":"150","author":"L M\u00f6bus","year":"2022","unstructured":"M\u00f6bus, L., et al.: Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. J. Allergy Clin. Immunol.Clin. Immunol. 150, 385\u2013395 (2022)","journal-title":"J. Allergy Clin. Immunol.Clin. Immunol."},{"key":"2_CR11","doi-asserted-by":"crossref","unstructured":"Tomalin, L.E., et al.: Early quantification of systemic inflammatory proteins predicts long-term treatment response to Tofacitinib and Etanercept. J. Investigative Dermatol. 140, 1026\u20131034 (2020)","DOI":"10.1016\/j.jid.2019.09.023"},{"key":"2_CR12","doi-asserted-by":"crossref","unstructured":"Hamilton, J., et al.: Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 134, 1293\u20131300 (2014)","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"2_CR13","doi-asserted-by":"crossref","unstructured":"Hu, Y., et al.: Identification of diagnostic immune-related gene biomarkers for predicting heart failure after acute myocardial infarction. Open Med., 18 (2023)","DOI":"10.1515\/med-2023-0878"},{"key":"2_CR14","doi-asserted-by":"crossref","unstructured":"Wang, X., Yu, G.: Drug discovery in canine pyometra disease identified by text mining and microarray data analysis. Biomed. Res. Int., 2023 (2023)","DOI":"10.1155\/2023\/7839568"},{"key":"2_CR15","doi-asserted-by":"crossref","unstructured":"Miller, J.A., et al.: Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinform., 12 (2011)","DOI":"10.1186\/1471-2105-12-322"},{"key":"2_CR16","doi-asserted-by":"crossref","unstructured":"Behdenna, A., et al.: pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods. BMC Bioinform., 24 (2023)","DOI":"10.1186\/s12859-023-05578-5"},{"key":"2_CR17","unstructured":"Brownlee, J.: Tour of Evaluation Metrics for Imbalanced Classification. https:\/\/machinelearningmastery.com\/tour-of-evaluation-metrics-for-imbalanced-classification\/"}],"container-title":["Lecture Notes in Computer Science","Progress in Artificial Intelligence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-73500-4_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T17:19:19Z","timestamp":1743182359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-73500-4_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"ISBN":["9783031734991","9783031735004"],"references-count":17,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-73500-4_2","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"type":"print","value":"0302-9743"},{"type":"electronic","value":"1611-3349"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"16 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"EPIA","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"EPIA Conference on Artificial Intelligence","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Viana do Castelo","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Portugal","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2024","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"3 September 2024","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"6 September 2024","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"23","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"epia2024","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/epia2024.pt","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}